0001354457-24-000082.txt : 20240215
0001354457-24-000082.hdr.sgml : 20240215
20240215085423
ACCESSION NUMBER: 0001354457-24-000082
CONFORMED SUBMISSION TYPE: 25-NSE
CONFIRMING COPY:
PUBLIC DOCUMENT COUNT: 2
FILED AS OF DATE: 20240215
DATE AS OF CHANGE: 20240215
SUBJECT COMPANY:
COMPANY DATA:
COMPANY CONFORMED NAME: Axcella Health Inc.
CENTRAL INDEX KEY: 0001633070
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 25-NSE
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38901
BUSINESS ADDRESS:
STREET 1: 840 MEMORIAL DRIVE
STREET 2: THIRD FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-868-0949
MAIL ADDRESS:
STREET 1: 840 MEMORIAL DRIVE
STREET 2: THIRD FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER COMPANY:
FORMER CONFORMED NAME: Pronutria Biosciences, Inc.
DATE OF NAME CHANGE: 20150206
FILED BY:
COMPANY DATA:
COMPANY CONFORMED NAME: Nasdaq Stock Market LLC
CENTRAL INDEX KEY: 0001354457
ORGANIZATION NAME:
IRS NUMBER: 521165937
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 25-NSE
BUSINESS ADDRESS:
STREET 1: One Liberty Plaza
CITY: New York
STATE: NY
ZIP: 10006
BUSINESS PHONE: 301-978-4144
MAIL ADDRESS:
STREET 1: Office of General Counsel
STREET 2: 805 King Farm Blvd.
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
FORMER COMPANY:
FORMER CONFORMED NAME: The Nasdaq Stock Market LLC
DATE OF NAME CHANGE: 20060224
25-NSE
1
primary_doc.xml
X0203
0001354457
Nasdaq Stock Market LLC
0001633070
Axcella Health Inc.
001-38901
840 Memorial Drive
Cambridge
MA
MASSACHUSETTS
02139
857-320-2200
Common stock
17 CFR 240.12d2-2(b)
Aravind Menon
Hearings Advisor
2024-02-15
EX-99.25
2
axladelistreason.txt
Delisting Determination, The Nasdaq Stock Market, LLC, February 15, 2024,
Axcella Health.
The Nasdaq Stock Market LLC (the Exchange) has determined
to remove from listing the securities of Axcella Health,
effective at the opening of the trading session on
February 26, 2024.
Based on review of information provided by the Company,
Nasdaq Staff determined that the Company no longer
qualified for listing on the Exchange pursuant to Listing
Rule 5450(a)(1). The Company was notified of the Staff
determination on June 29, 2023. On July 6, 2023, the
Company exercised its right to appeal the Staff determination
to the Listing Qualifications Hearings Panel (Panel) pursuant
to Rule 5815.
On August 16, 2023, upon review of the information provided
by the Company, the Panel determined to grant the Company
request to remain listed in the Exchange subject to a series
of milestones.
On October 3, 2023, the Company received an additional delist
determination for its failure to meet the requirements in
Listing Rules 5450(b)(2)(A) and Listing Rule 5450(b)(2)(C).
On November 8, 2023, the Company received an additional delist
determination letter pursuant to Staff attributions under
Listing Rule 5101. Additionally, on November 16, 2023, the
Company was issued a new delist determination for its
failure to meet the requirements in Listing Rule 5250(c)(1).
On November 21, 2023, the Panel issued a final decision denying
the Company continued listing. The Company securities were
suspended on November 24, 2023. The Company did not appeal the
Panel decision to the Nasdaq Listing and Hearing Review Council
(Council) and the Council did not call the matter for review.
The Staff determination to delist the Company became final on
January 8, 2024.